La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Herantis Pharma Oyj Crescita futura

Future criteri di controllo 0/6

Si prevede che i ricavi e gli utili di Herantis Pharma Oyj diminuiranno rispettivamente del 49.9% e 37.1% all'anno, mentre si prevede che l'EPS diminuirà del 27.3% all'anno.

Informazioni chiave

-37.1%

Tasso di crescita degli utili

-27.3%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	15.3%
Tasso di crescita dei ricavi	-49.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	01 Jul 2024

Aggiornamenti recenti sulla crescita futura

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

Previsioni di crescita degli utili e dei ricavi

HLSE:HRTIS - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-6	-6	-6	1
12/31/2025	N/A	-5	0	-5	2
12/31/2024	1	-4	-7	-7	2
12/31/2023	N/A	0	-5	-5	N/A
9/30/2023	N/A	-3	-5	-5	N/A
6/30/2023	N/A	-5	-5	-5	N/A
3/31/2023	N/A	-7	-7	-7	N/A
12/31/2022	N/A	-9	-9	-9	N/A
9/30/2022	N/A	-10	-9	-9	N/A
6/30/2022	N/A	-10	-10	-10	N/A
3/31/2022	N/A	-12	-10	-10	N/A
12/31/2021	N/A	-13	-10	-10	N/A
9/30/2021	N/A	-13	-10	-10	N/A
6/30/2021	N/A	-13	-9	-9	N/A
3/31/2021	N/A	-11	-9	-9	N/A
12/31/2020	N/A	-9	-9	-9	N/A
9/30/2020	N/A	-9	-8	-8	N/A
6/30/2020	N/A	-9	-8	-8	N/A
3/31/2020	N/A	-9	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-7	-5	-5	N/A
6/30/2019	N/A	-6	-5	-5	N/A
3/31/2019	N/A	-5	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-3	-4	-4	N/A
6/30/2018	N/A	-2	-3	-3	N/A
3/31/2018	N/A	-2	-3	-3	N/A
12/31/2017	N/A	-2	-3	-3	N/A
9/30/2017	N/A	-3	N/A	-2	N/A
6/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	0	-4	N/A	-2	N/A
12/31/2016	0	-4	N/A	-3	N/A
9/30/2016	0	-5	N/A	-4	N/A
6/30/2016	0	-5	N/A	-4	N/A
3/31/2016	0	-11	N/A	-6	N/A
12/31/2015	0	-16	N/A	-7	N/A
9/30/2015	0	-18	N/A	-7	N/A
6/30/2015	0	-19	N/A	-7	N/A
3/31/2015	0	-15	N/A	-6	N/A
12/31/2014	0	-8	N/A	-4	N/A
9/30/2014	0	-6	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di HRTIS diminuiranno nei prossimi 3 anni ( -37.1% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di HRTIS diminuiranno nei prossimi 3 anni ( -37.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HRTIS diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di HRTIS diminuiranno nei prossimi 3 anni ( -49.9% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di HRTIS diminuiranno nei prossimi 3 anni ( -49.9% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di HRTIS è previsto essere elevato tra 3 anni

Herantis Pharma Oyj Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Recent updates

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita